Search | Clinical Trials Finder

Conditions: Kallmann Syndrome, Idiopathic Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions: gonadotropin releasing hormone (GnRH); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women, Agonadism
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Amenorrhea With Hypogonadotropic Hypogonadism
Interventions: Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 33
States / cities: Tempe, Arizona • San Francisco, California • Aurora, Colorado + 28 more

Conditions: Hypogonadism, Hypogonadism, Male
Interventions: Nanomilled testosterone, commercially available dutasteride, Nanomilled dutasteride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Male Hypogonadism
Interventions: Testosterone; Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 30
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 26 more

Conditions: Hypogonadism
Interventions: GnRH antagonist (Acyline); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadotropic Hypogonadism, Amenorrhea, Kallmann's Syndrome
Interventions: GnRH, Pump; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Klinefelter Syndrome, XXY Syndrome
Interventions: Testosterone gel 1%, Placebo gel; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 18 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Obesity, Infertility, Hypogonadotropic Hypogonadotropism, Hyperinsulinemia
Interventions: Insulin, Intralipid, Dextrose, Heparin, GnRH, Hyperinsulinemic Euglycemic Clamp; Drug · Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypogonadotropic Hypogonadism
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadism, Male
Interventions: Testosterone Cypionate Injection 200 mg/mL; Drug
Lead sponsor: Azurity Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 3 more

Conditions: Amenorrhea, Hypogonadotropic Hypogonadism, Kallmann's Syndrome
Interventions: Frequent baseline blood sampling; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Spinal Cord Injury, Spinal Cord Injuries, Injuries, Spinal Cord, Spinal Cord Contusion, Spinal Cord Trauma, Trauma, Nervous System, Wounds and Injuries, Spinal Cord Compression, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions: testosterone cypionate, finasteride, placebo injection, placebo pill; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 4
States / cities: Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 1 more

Conditions: Hypogonadism
Interventions: anastrozole; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years and older · Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadism
Interventions: AndroGel 1.62%; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 45
States / cities: Foley, Alabama • Newport Beach, California • Northridge, California + 40 more

Conditions: Hypogonadism
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 200 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypogonadism
Interventions: Testosterone, Placebo; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years to 85 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Hypogonadism
Interventions: Test: Follitropin alfa, Reference: Follitropin alfa, Zoladex; Combination Product · Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hypogonadotropic Hypogonadism, Low Testosterone
Interventions: Naloxone; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
Interventions: Testosterone Undecanoate 750 mg, Testosterone Undecanoate 1000 mg; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Hypogonadism, Cardiovascular Diseases
Interventions: AndroGel®, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 5,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 379
States / cities: Alabaster, Alabama • Birmingham, Alabama • Decatur, Alabama + 262 more

Conditions: Hypogonadism, Metabolic Syndrome, Diabetes, Inflammation
Interventions: Pioglitazone; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Klinefelter Syndrome
Interventions: testosterone cypionate 200mg/ml; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 42 Days to 108 Days · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypogonadism
Interventions: 10.0 mg of Testosterone, 4.0% TID, 13.5 mg of Testosterone, 4.5% B.I.D, 11.25 mg of Testosterone, 4.5% T.I.D; Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Tucson, Arizona • Miami, Florida • Shreveport, Louisiana

Search by objective public record fields.

Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

LutrePulse Hypogonadotropic Hypogonadism

Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride

Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism

Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men

Pulsatile GnRH in Anovulatory Infertility

Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome

Reprometabolic Syndrome Mediates Subfertility in Obesity

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men

Baselines in Reproductive Disorders

Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

Anastrozole Administration in Elderly Hypogonadal Men

A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Psychological Outcomes in Isolated GnRH Deficiency

Cycled Testosterone Replacement Study

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

Opioid Antagonism in Hypogonadotropic Hypogonadism

Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

Androgen Deprivation Therapy Study

Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment

Efficacy of an Intranasal Testosterone Product